John Libbey Eurotext

Dermato Mag

MENU

Actualités thérapeutiques en dermatologie libérale (Journées Nationales Provinciales de Dermatologie, Le Havre, mars 2019) Volume 7, numéro 3, Juillet-Août-Septembre 2019

  • [1] Ferrer Guillén B., Macarena Giàcarman M., Valenzuela Oñate C., Magdaleno Tapial J., Hernandez Bel P., Pérez Ferriols A. Pirfenidone-induced photosensitivity confirmed by pathological phototest. Photodiagnosis Photodyn Ther. 2019;25:103-105.
  • [2] Schmutz J.L. Pirfenidone (Esbriet®) : attention au soleil ! Ann Dermatol Venereol. 2018;145:811-812.
  • [3] Sugino K., Kabuki T., Shibuya K., Homma S. Systemic scleroderma-related interstitial pneumonia associated with borderline pulmonary arterial hypertension. BMJ Case Rep. 2018;26.
  • [4] Mendoza F.A., Mansoor M., Jimenez S.A. Treatment of Rapidly Progressive Systemic Sclerosis: Current and Futures Perspectives. Expert Opin Orphan Drugs. 2016;4:31-47.
  • [5] Volkmann E.R., Tashkin D.P. Treatment of Systemic Sclerosis-related Interstitial Lung Disease: A Review of Existing and Emerging Therapies. Ann Am Thorac Soc. 2016;13:2045-2056.
  • [6] Melosky B., Leighl N.B., Rothenstein J., Sangha R., Stewart D., Papp K. Management of egfr tki-induced dermatologic adverse events. Curr Oncol. 2015;22:123-132.
  • [7] Chu C.Y., Choi J., Eaby-Sandy B., Langer C.J., Lacouture M.E. Osimertinib: A Novel Dermatologic Adverse Event Profile in Patients with Lung Cancer. Oncologist. 2018;23:891-899.
  • [8] Cubiró X., Planas-Ciudad S., Garcia-Muret M.P., Puig L. Topical Timolol for Paronychia and Pseudopyogenic Granuloma in Patients Treated With Epidermal Growth Factor Receptor Inhibitors and Capecitabine. JAMA Dermatol. 2018;154:99-100.
  • [9] Piraccini B.M., Alessandrini A., Dika E., Starace M., Patrizi A., Neri I. Topical propranolol 1 % cream for pyogenic granulomas of the nail : open-label study in 10 patients. J Eur Acad Dermatol Venereol. 2016;30:901-902.
  • [10] Oro S., Bernier C., Gener G., Barbaud A., Lebrun-Vignes B., Assier H. Valaciclovir : un coupable de DRESS à ne pas négliger. Deux Cas. Poster 025. Ann Dermatol Venereol. 2018;145:S148.
  • [11] Kanzler M.H. Reevaluating the Need for Laboratory Testing in the Treatment of Onychomycosis: Safety and Cost-effectiveness Considerations. JAMA Dermatol. 2016;152:263-264. 3
  • [12] Kramer O.N., Albrecht J. Clinical presentation of terbinafine-induced severe liver injury and the value of laboratory monitoring: A critically appraised Topic. Br J Dermatol. 2017;177:1279-1284.
  • [13] Stolmeier D.A., Stratman H.B., McIntee T.J., Erik J., Stratman E.J. Utility of laboratory test result monitoring in patients taking oral terbinafine or griseofulvin for dermatophyte infections. JAMA Dermatol. 2018;154:1409-1416.
  • [14] Arnspang S., Gaist D., Johannesdottir Schmidt S.A. Hydrochlorothiazide use and risk of non-melanoma skin cancer: A nationwide case-control study from Denmark. J Am Acad Dermatol. 2018;78:673-681.
  • [15] Pottegard A., Hallas J., Olesen M. Hydrochlorothiazide use is strongly associated with risk of lip cancer. J Intern Med. 2017;282:322-331.
  • [16] Friedman G.D., Asgari M.M., Warton E.M., Chan J., Hable L.A. Antihypertensive drugs and lip cancer in non-hispanic whites. Arch Intern Med. 2012;172:1246-1251.
  • [17] Pottegard A., Pedersen S.A., Schmidt S.A.J., Holmich L.R., Friis S., Gaist D. Association of hydrochlorothiazide use and risk of malignant melanoma. JAMA Intern Med. 2018;178:1120-1122.
  • [18] Pedersen S.A., Johannesdottir Schmidt S.A., Hölmich L.R., Friis S., Pottegård A., Gaist D. Hydrochlorothiazide use and risk for Merkel cell carcinoma and malignant adnexal skin tumors : a nationwile case-control study. J Am Acad Dermatol. 2019;80:460-465.
  • [19] van Veelen A, Nielen JTH, van Geel R, Croes S. Response to ‘Hydrochlorothiazide use and risk of nonmelanoma skin cancer : a nationwide case-control study from Denmark. J Am Acad Dermatol 2019 Feb 13. pii : S0190-9622(19)30274-9. doi : 10.1016/j.jaad.2019.01.087.[Epub ahead of print].
  • [20] Gandini S., Palli D., Spadola G. Anti-hypertensive drugs and skin cancer risk: A review of the literature and metaanalysis. Crit Rev Oncol Hematol. 2018;122:1-9.
  • [21] Pedersen SA, Pottegård A. Reply to ”Response to Hydrochlorothiazide use and risk of nonmelanoma skin cancer: A nationwide case-control study from Denmark. J Am Acad Dermatol 2019 Feb 13. pii : S0190-9622(19)30274-9. doi : 10.1016/j.jaad.2019.01.087.[Epub ahead of print].
  • [22] Schmutz J.L. Hydrochlorothiazide et cancers cutanés. Ann Dermatol Venereol. 2018;145:225-226.
  • [23] Schmutz J.L. L’hydrochlorothiazide augmenterait le risque de mélanome. Ann Dermatol Venereol. 2018;145:643-644.
  • [24] Mahé A. Les thiazidiques sur la sellette. Quoi de neuf en 2018-JDP 2018. Ann Dermatol Venereol. 2018VIIS6.
  • [25] Heymann W.R. The expanding saga of hydrochlorothiazide and skin cancer. J Am Acad Dermatol. 2019;80:380-381.
  • [26] Wright J.M., Musini V.M., Gill R. First-line drugs for hypertension. Cochrane Database Syst Rev. 2018;4:CD001841.
  • [27] Michael Cameron M.C., Lee E., Hibler B.P. Basal cell carcinoma, Epidemiology; pathophysiology; clinical and histological subtypes; and disease associations. J Am Acad Dermatol. 2019;80:303-317.
  • [28] Ramdas K., van Lee C., Beck S. Differences in rate of complete excision of basal cell carcinoma by dermatologists, plastic surgeons and general practitioners: A large cross-sectional study. Dermatology. 2018;243:86-91.
  • [29] Harper N.J.N., Cook T.M., Garcez T. Anaesthesia, surgery, and life-threatening allergic reactions: Epidemiology and clinical features of perioperative anaphylaxis in the 6th National Audit Project (NAP6). Br J Anaesth. 2018;121:159-217.
  • [30] Rastogi S., Patel K.R., Singam V., Silverberg J.I. Allergic contact dermatitis to personal care products and topical medications in adults with atopic dermatitis. J Am Acad Dermatol. 2018;79:1028-1033.
  • [31] Barnes S, Stuart R, Redley B. Health care worker sensitivity to chlorhexidine-based hand hygiene solutions : A cross-sectional survey. Am J Infect Control 2019 Feb 11. pii : S0196-6553(19)30025-2. doi : 10.1016/j.ajic.2019.01.006.[Epub ahead of print].
  • [32] Beaumont C, Ferrier Le Bouëdec MC, D’Incan M. Eczémas de contact à la Biseptine® : une série de 14 patients. Communication orale, GERDA Dijon, 2018.
  • [33] Darrigade A.S., Léauté-Labrèze C., Boralevi F., Taïeb A., Milpied B. Allergic contact reaction to antiseptics in very young children. J Eur Acad Dermatol Venereol. 2018;32:2284-2287.
  • [34] Le Corre Y., Barbarot S., Frot A.S., Milpied B. Allergic Contact Dermatitis to Chlorhexidine in a Very Young Child. Pediatric Dermatol. 2010;27:485-487.
  • [35] Mathelier-Fusade P. Allergies de contact à la chlorhexidine chez le jeune enfant. Ann Dermatol Venereol. 2018;145:S145.
  • [36] Aerts O., De Fré C., van Hoof T., Ghys K., Ortopelea R.A., Lambert J. ”Slime”: A new fashion among children causing severe hand dermatitis. Contact Dermatitis. 2018;79:385-438.
  • [37] Kondratuk K.E., Norton S.A. “Slime” dermatitis, a fad-associated chronic hand dermatitis. Pediatr Dermatol. 2019;36:e39-e40. 1
  • [38] Heller E., Murthy A.S., Jen M.V. A slime of the times: Two cases of acute irritant contact dermatitis from homemade slime. Pediatr Dermatol. 2019;36:139-141.
  • [39] Zhang A.J., Boyd A.H., Asch S., Warshaw E.M. Allergic contact dermatitis to slime: The epidemic of isothiazolinone allergy encompasses school glue. Pediatr Dermatol. 2019;36:e37-e38. 1
  • [40] Salman A., Demir G., Apti O. ”Slime”: A trending cause of isothiazolinone contact allergy in children. Contact Dermatitis. 2019;80:409-411. 6
  • [41] Salomon G, Giordano-Labadie F. Eviction de la méthylisothiasolinone : pas facile en pratique. Ann Dermatol Venereol 2018 ; 145 : S.
  • [42] Cordel N. Le défi « Ventoline ». Ann Dermatol Venereol 2018 ; 145 : S.
  • [43] Noguera-Morel L., Gerlero P., Torrelo A., Hernández-Martín Á. Ivermectin therapy for papulopustular rosacea and periorificial dermatitis in children: A series of 15 cases. J Am Acad Dermatol. 2017;76:567-570.
  • [44] Pöyhönen H., Nurmi M., Peltola V., Alaluusua S., Ruuskanen O., Lähdesmäki T. Dental staining after doxycycline use in children. J Microb Chemother. 2017;72:2887-2890.
  • [45] Bremell D, Trollfors B. Doxycycline can be given to children without risk of staining of teeth. Lakartidningen 2017 Aug 23 ; 114. pii : ERIC.
  • [46] Gaillard T., Briolant S., Madamet M., Pradines B. The end of a dogma: The safety of doxycycline use in young children for malaria treatment. Malar J. 2017;16:148.
  • [47] Todd S.R., Dahlgren F.S., Traeger M.S. No visible dental staining in children treated with doxycycline for suspected Rocky Mountain spotted fever. J Pediatr. 2015;166:1246-1251.
  • [48] Bos B., Antonescu I., Osinga H., Veenje S., de Jong K., de Vries T.W. Corticosteroid phobia (corticophobia) in parents of young children with atopic dermatitis and their health care providers. Pediatr Dermatol. 2019;36:100-104.
  • [49] Karagounis T.K., Gitter J.K., Rotemberg V., Morel K.D. Use of « natural » oils for moisturization: Review of olive, coconut, sunflower seed oil. Pediatr Dermatol. 2019;36:9-15.
  • [50] Patel K.R., Supriya Immaneni S., Singam V., Rastogi S., Silverberg J.I. Association between atopic dermatitis, depression, and suicidal ideation: A systematic review and meta-analysis. J Am Acad Dermatol. 2019;80:402-410.
  • [51] Yang E.J., Beck K.M., Sekhon S., Bhutani T., Koo J. The impact of pediatric atopic dermatitis on families: A review. Pediatr Dermatol. 2019;36:66-71.
  • [52] Misery L., Seneschal J., Reguai Z. The impact of atopic dermatitis on sexual health. J Eur Acad Dermatol Venereol. 2019;33:428-432.
  • [53] Misery L., Seneschal J., Reguiai Z. Patient Burden is Associated with Alterations in Quality of Life in Adult Patients with Atopic Dermatitis: Results from the ECLA Study. Acta Derm Venereol. 2018;98:713-714.
  • [54] Eckert L., Gupta S., Amand C., Gadkari A., Mahajan P., Gelfand J.M. Impact of atopic dermatitis on health-related quality of life and productivity in adults in the United States: An analysis using the national Health and Wellness Survey. J Am Acad Dermatol. 2017;77:274-279.
  • [55] Zink A.G.S., Arents B., Fink-Wagner A. Out-of-pocket Costs for Individuals with Atopic Eczema: A Cross-sectional Study in Nine European Countries. Acta Derm Venereol. 2019;99:263-267. 3
  • [56] Launois R, Ezzedine K, Cabout E, et al. Importance of out-of-pocket costs for adult patients with atopic dermatitis in France. JEADV 2018. 1979 R2. [Epud ahead of print]. Poster. ISPOR 21the Annual European Congress. 10-14 Nov 2018. Barcelona.
  • [57] Anderson K., Putterman E., Rogers R.S., Patel D., Treat J.R., Castelo-Soccio L. Treatment of severe pediatric atopic dermatitis with methotrexate: A retrospective review. Pediatr Dermatol. 2019;00:1-5.
  • [58] Dvorakova V., O’Regan G.M., Irvine A.D. Methotrexate for severe childhood atopic dermatitis: Clinical experience in a tertiary center. Pediatr Dermatol. 2017;34:528-534.
  • [59] Bouvenot G, Juillet Y, Saint-Pierre A, Serre MP ; au nom du groupe de travail inter-académique de l’Académie nationale de médecine et de l’Académie nationale de pharmacie. Les Prescriptions médicamenteuses hors AMM (Autorisation de Mise sur le Marché) en France. Une clarification est indispensable. Mardi 20 novembre 2018.